SecBot SecBot
6-K ·Filed Jul 8, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001395064-26-000278
Notable filing: 6-K
Actionable Insight • Neutral

Routine compensation-related share issuance with no material financial impact. No trading action warranted. Monitor next quarterly results for any updates on employee incentive plan costs.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$16.75
T+0 close · Jul 8, 2026 · via day close
Latest settled
+6.63%
T+60 · $17.86
Vs SPY
+4.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 8 $16.75entry
  2. T+1 · 4mo ago −0.84%α −1.68% · $16.61
  3. T+5 · 4mo ago −2.15%α −3.01% · $16.39
  4. T+20 · 3mo ago −0.18%α −3.45% · $16.72
  5. T+60 · 7w ago +6.63%α +4.13% · $17.86
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Takeda completed the issuance of 16.88 million ordinary shares (including treasury shares) at 5,050 yen per share under its employee long-term incentive plan, with a slight reduction from the original plan due to forfeiture of rights. The company states the impact on full-year financials is immaterial. This is a routine administrative update with no material effect on the stock.

Key Facts

  • Issued 16,877,109 ordinary shares (10,780,950 new shares + 6,096,159 treasury shares) at 5,050 yen per share
  • Total value approximately 85.2 billion yen
  • Partial forfeiture of rights reduced the number of shares from originally planned 16,989,076
  • Company says immaterial impact on FY2027 financials

Financial Impact

Total value of shares issued and disposed is approximately 85.2 billion yen (about 16.88 million shares at 5,050 yen per share), but the company explicitly states the impact on full-year financials is immaterial

dilutionshare count

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
68% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001395064-26-000278
Document: 0001395064-26-000278-index-headers.html0001395064-26-000278
Document: 0001395064-26-000278-index.html0001395064-26-000278
Document: 0001395064-26-000278.txt0001395064-26-000278

Track record

18 reports on TAK

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $21.19 to $21.12 Now $21.59 +1.89% ▼ −0.33% −3.62% vs SPY
  2. Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
  3. Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
  4. Oct 29, 202618d ago 6-K Neutral 4/10 No price data
  5. Oct 29, 202618d ago 6-K Bearish 5/10 Entry $20.01 to $21.19 Now $21.59 −7.90% ▼ −5.90% −10.62% vs SPY
  6. Sep 14, 20269w ago 6-K Bullish 7/10 Entry $18.60 to $18.89 Now $21.59 +16.08% ▲ +1.56% +1.45% vs SPY
  7. Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $18.24 to $17.98 Now $21.59 +18.37% ▼ −1.43% −1.89% vs SPY
  8. Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $18.13 to $18.03 Now $21.59 +19.08% ▼ −0.55% −1.67% vs SPY
  9. Aug 14, 202613w ago Court Ruling Neutral 4/10 Entry $17.38 to $18.24 Now $21.59 +24.22% ▲ +4.95% +6.14% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 3/10 Entry $17.39 to $18.13 Now $21.59 +24.15% ▲ +4.26% +6.22% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 8h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 8, 2026